No photo available
Our firm is representing for sale exclusive rights to ORALMEDIC® Mouth Ulcer Treatment, an over-the-counter (“OTC”) patented product used to alleviate canker sore pain in seconds. ORALMEDIC's initial sales started 12 years ago in Europe and has expanded into Canada and Asia over the past 8 years. It has not yet been approved for OTC sale in the U.S. and is not distributed in the U.S.
Once applied to a canker sore, or commonly referred also to as a mouth ulcer, ORALMEDIC stops the pain and discomfort within seconds of one application. This product immediately promotes natural healing of the ulcer and closure can happen in 3-5 days vs other products at 12-14 days.
Recurring mouth ulcers represent a large market - affecting up to 30% of the general population, with frequency of recurrence of the painful lesions ranging from two to four episodes per year (at the low end) to an almost continuous chain of outbreaks in the mouth. Each occurrence typically lasts from four to ten days.
EPIEN projects 2020 net revenues to double from 2019 levels to $617k, representing a 10.8% CAGR from 2017.
EPIEN is selling the exclusive rights to ORALMEDIC in Europe, Canada, the Middle East, Africa, and Central and South America. Due to a previous exclusive licensing agreement rights to Hong Kong, Mainland China, Singapore and South Korea are not available, but many other large APAC markets including Australia, India, Japan, and the Philippines offer large expansion opportunities. The figures in this executive summary reflect ORALMEDIC only in these markets that would be included in this transaction.
More information available upon request.
Learn More About This Listing
Sign up for a free basic membership to start buying and selling. Learn about our membership plans.
Disclaimer: DealStream has not independently verified any of the information in this listing and makes no warranty as to its accuracy or completeness.